TALPHERA, INC. quarterly report, Q3 FY2013

Business context and reporting period

This is AcelRx Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2013. Although the request identifies Talphera, the filing itself names AcelRx Pharmaceuticals, Inc. The company was a development-stage specialty pharmaceutical business focused on acute and breakthrough pain; it had no product sales and was funded mainly by equity offerings and debt.

Financial performance and position

Amounts below are in millions of dollars except per-share data. Revenue consisted of research-grant revenue, not commercial product revenue.

• Cash flow: Operating cash use was $25.935 million for the first nine months of 2013, versus $18.783 million in 2012. Investing used $4.838 million; financing provided $43.636 million. Cash and cash equivalents rose $12.863 million to $60.795 million.
• Liquidity: Cash, cash equivalents and investments totaled $75.968 million at September 30, 2013, compared with $59.763 million at year-end 2012. Current assets were $76.999 million and current liabilities $12.428 million, implying working capital of approximately $64.571 million.
• Debt: Debt carrying amount was approximately $10.5 million, down from $16.0 million at December 31, 2012; the Hercules loan bears 8.5% interest and matures December 1, 2014. Monthly principal-and-interest payments were about $742,000.
• Margins: Commercial gross margin is not applicable because the company had no product sales. The filing reports operating and net losses rather than a meaningful product margin.

Material changes versus prior comparable periods

• Q3 net loss increased by $2.404 million year over year despite lower R&D expense; the quarter included $2.328 million of net other expense, primarily reflecting remeasurement of liability-classified warrants.
• Nine-month net loss increased by $18.354 million. Net other expense was $13.340 million, chiefly from the warrant liability’s fair-value increase; this was a significant non-cash item. The cash-flow reconciliation included $13.612 million for revaluation of warrant and option liabilities.
• Nine-month R&D expense rose 28%, principally from ARX-04 development, higher Zalviso-related expense including the filing fee, and personnel costs. Q3 R&D declined 6% as Phase 3 activity wound down, partly offset by the $1.95 million Zalviso NDA fee.
• Nine-month G&A increased 24%, reflecting personnel, consulting, market research, and legal costs. The July 2013 public offering generated $47.9 million net proceeds; shares outstanding increased to 43,039,269 from 37,055,027 at December 31, 2012.

Outlook, management commentary, risks and unusual items

• The company submitted the Zalviso NDA to the FDA on September 27, 2013. Management anticipated FDA filing in Q4 2013, a PDUFA review goal date in Q3 2014, and a possible U.S. launch in Q1 2015, all conditional on FDA filing and approval.
• Management expected cash resources to fund current operations through at least 2014, but stated additional financing or collaborations would be needed thereafter. It expected higher future cash use for development and commercialization preparation, and total 2013 operating expenses modestly above 2012. Q4 2013 R&D was expected to be lower than Q3.
• The FDA filing fee was $1.95 million after the Small Business Administration determined the company did not qualify for the small-business waiver. This was a one-time Q3 expense.
• The Zalviso Phase 3 program reported positive top-line results, but FDA acceptance, review, approval, labeling, and any additional study requirements remained uncertain. The product is a drug-device combination and contains the Schedule II opioid sufentanil.
• ARX-04’s Phase 2 trial met its primary endpoint; further development depended on additional resources. The Army grant had a no-cost extension through January 31, 2014, with approximately $0.2 million expected to be earned by then. Further ARX-02 and ARX-03 development depended on partnership resources.
• Manufacturing is outsourced. A Patheon agreement covers supply through 2017 and includes company payments of $480,000 in 2013 and a potential annual overhead fee up to $200,000; possible facility modifications were expected to cost less than $3.5 million, with additional costs possible.
• Key risks include financing needs and potential dilution, FDA or manufacturing delays, reliance on limited suppliers and government grant funding, clinical and regulatory uncertainty, commercialization and reimbursement challenges, and warrant-liability valuation volatility. The filing reported no material pending litigation, no defaults on senior securities, and no off-balance-sheet arrangements. Management concluded disclosure controls were effective.

Investor verification priorities

• Confirm the FDA’s subsequent NDA filing decision, review timeline, approval outcome, and any added study or labeling requirements for Zalviso.
• Assess cash burn and financing needs against management’s stated runway through at least 2014, including debt payments and launch-preparation costs.
• Track the warrant liability and its non-cash fair-value effects on reported earnings; distinguish those movements from operating cash use.
• Verify commercial manufacturing readiness, FDA inspection status, supply continuity, and actual costs under the Patheon arrangements.
• Monitor dilution from equity financing, warrants, options, and any future capital raises, as well as progress and funding for ARX-04.